Following the legalization of adult-use cannabis in Canada and a number of US states, North America is poised to be the largest market for the plant moving forward. According to Arcview Market Research and BDS Analytics, legal cannabis spending in North America could reach as much as US$47.3 billion by 2027.

The projected growth of cannabis spending and investment has seen a response in technical innovations, ranging in applications from cultivation, medicinal and consumer products, payment processing and data analytics. These developments are supporting licensed producers, retailers and cannabis researchers in effectively scaling their operations as the industry continues to expand.


Cannabis cultivation has seen a shift in what it means to run an agricultural operation. In the search for high yield and high-quality product, licensed producers have implemented technological solutions and cultivation techniques like using tissue culture to produce identical clones in a sterile environment.

A more established market than that of adult-use, the medicinal cannabis space has also seen innovations in consumption methods in the form of vaporizer pens and oils and tinctures. Oils and extracts are easily measured, making them for accurate from a dosing perspective. Consumer products have also advanced in number with the likes of nanotechnology formulations and topicals emerging on the scene.

On the retail side, fintech and cashless payment processing solutions are being developed using blockchain technology to protect against fraud and theft. As the market ages, there will also be more and more data to collect and analyze with analytics tools being designed specifically for cannabis producers, retailers, consumers and more.

Spurred by the current state of the market, these innovations will be pivotal in developing the cannabis industry, providing alternative routes for investors to engage with this growing space.

The following Visual Capitalist infographic, sponsored by The Valens Company (CSE:VLNS,OTC:MYMSF), will help investors learn more about the innovations spurring opportunity in the cannabis market:

Infographic courtesy of Visual Capitalist.

Click here for INN’s exclusive profile of The Valens Company. 

This infographic is sponsored by The Valens Company (CSE:VLNS,OTC:MYMSF). This infographic provides information which was sourced by the Investing News Network (INN) and approved by The Valens Company, in order to help investors learn more about the company. The Valens Company is a client of INN. The company’s campaign fees pay for INN to create and update this infographic.

This infographic was created according to INN editorial standards to educate investors.

INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.

The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with The Valens Company and seek advice from a qualified investment advisor.

Appointment of Dr. Kelmendi, Assistant Professor of Psychiatry at Yale University and co-founder of the Yale Psychedelic Science Group, brings another experienced medical professional to Lobe’s advisory team.

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the appointment of Benjamin Kelmendi, MD, Assistant Professor of Psychiatry at Yale University School of Medicine, to its Scientific Advisory Board.

Keep reading... Show less

Ayurcann Holdings Corp. ( CSE: AYUR ) (the “ Company ” or ” Ayurcann “), a Canadian extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, is pleased to unveil further details of its Phase 2 expansion plans.

Ayurcann has commenced trading on the Canadian Securities Exchange (” CSE “) on April 8, 2021 and subsequently announced a private placement of up to $500,000 (” Financing “), as per the Company’s press release dated April 12, 2021. The proceeds of the Financing are intended to be used to further pursue Phase 2 of the expansion of the production capacity of the Company’s Pickering facility.

Keep reading... Show less

New findings suggest the COVID-19 pandemic, combined with expanded state legalization, has attracted new consumers to the category and accelerated cannabis acceptance and adoption.

  • YouGov study indicates the number of current cannabis consumers has increased 56% within just two years compared to the 16% of Americans who reported current consumption in 2018.
  • 23% of current consumers say they tried cannabis for the first time within the past year.
  • More than half of cannabis consumers say they will purchase or try a new product or format this 420, indicating that the holiday is becoming increasingly focused on exploration and trial.

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or the “Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, released the results of a survey today showing one in four Americans currently consume cannabis, reporting they’ve tried some form of cannabis within the past twelve months. That’s a significant increase since 2018* when just 16% of U.S. adults reported current consumption, representing a 56% increase in just two years. What’s more, 23% of current cannabis consumers say they tried cannabis for the first time over the past year, suggesting the COVID-19 pandemic, combined with expanded state legalization, has rapidly accelerated cannabis acceptance and adoption in America.

Keep reading... Show less

Acquires Three Operating Dispensaries in Northeast Pennsylvania

Purchase price represents a mid-single digit multiple of KCR’s expected 2021 EBITDA

Keep reading... Show less